# OnCo record gadoquatrane (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/gadoquatrane/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "gadoquatrane" ;
  schema:name "Gadoquatrane"@en ;
  schema:alternateName "gadoquatrane"@en, "Ambelvist"@en, "Ambelvist" ;
  schema:description "A gadolinium MRI dye approved in the United States in 2026 for brain and body scans."@en ;
  schema:url <https://onco.cc/drugs/gadoquatrane/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219627>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fac80f5d-8d37-4237-bb52-0faef0dd46aa>, <https://atcddd.fhi.no/atc_ddd_index/?code=V08CA&showdescription=no> ;
  onco:status "approved" ;
  onco:tag "contrast-agents-gaps-2026-11", "diagnostic" ;
  onco:modality "Gadolinium-based contrast agent for MRI of the brain and body (intravenous)" ;
  onco:approval "US 2026: MRI of lesions with abnormal vascularity in the central nervous system and the body" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/secondary-brain-tumours/> ;
  onco:technologies <https://onco.cc/technologies/gadolinium-based-contrast-agents/>, <https://onco.cc/technologies/mri/> ;
  onco:companies <https://onco.cc/companies/bayer/> .